Sign up to save your podcasts
Or
Share Beyond Bariatric Surgery: Retatrutide and the 30% Weight Loss Frontier 🚀
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Beyond Bariatric Surgery: Retatrutide and the 30% Weight Loss Frontier 🚀
⚖️🚀 RETATRUTIDE may redefine obesity medicine.
In the Phase 3 TRIUMPH-1 trial, Lilly's triple agonist (GIP/GLP-1/glucagon) achieved an astonishing 28.3% average weight loss at 80 weeks, with some patients exceeding 30% weight reduction — territory once associated mainly with bariatric surgery. 📉
Even the 4 mg dose achieved nearly 20% weight loss with fewer discontinuations. Significant improvements were also seen in waist circumference, triglycerides, systolic BP, and hsCRP. ❤️
A fascinating glimpse into the future of cardiometabolic therapeutics.
🎙️ Dr RR Baliga's Podkast for the Kurious Doc
#Obesity #Retatrutide #GLP1 #Cardiology #Endocrinology #WeightLoss #Medical
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
⚖️🚀 RETATRUTIDE may redefine obesity medicine.
In the Phase 3 TRIUMPH-1 trial, Lilly's triple agonist (GIP/GLP-1/glucagon) achieved an astonishing 28.3% average weight loss at 80 weeks, with some patients exceeding 30% weight reduction — territory once associated mainly with bariatric surgery. 📉
Even the 4 mg dose achieved nearly 20% weight loss with fewer discontinuations. Significant improvements were also seen in waist circumference, triglycerides, systolic BP, and hsCRP. ❤️
A fascinating glimpse into the future of cardiometabolic therapeutics.
🎙️ Dr RR Baliga's Podkast for the Kurious Doc
#Obesity #Retatrutide #GLP1 #Cardiology #Endocrinology #WeightLoss #Medical
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
906 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
The Mel Robbins Podcast
20,222 Listeners